Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Lowered to $41.00 at Bank of America

Agios Pharmaceuticals (NASDAQ:AGIO) had its target price decreased by Bank of America from $44.00 to $41.00 in a research report sent to investors on Tuesday,Benzinga reports. Bank of America currently has a buy rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued research reports about the stock. Leerink Partners upped their price target on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, December 26th. JPMorgan Chase & Co. upped their price target on shares of Agios Pharmaceuticals from $31.00 to $36.00 and gave the company a “neutral” rating in a research report on Monday, April 6th. Truist Financial upped their price target on shares of Agios Pharmaceuticals from $32.00 to $38.00 and gave the company a “buy” rating in a research report on Wednesday, December 24th. The Goldman Sachs Group upped their price target on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research report on Wednesday, April 1st. Finally, Citigroup upped their price target on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Agios Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $41.78.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ:AGIO opened at $26.29 on Tuesday. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of -3.70 and a beta of 0.79. Agios Pharmaceuticals has a 1-year low of $22.24 and a 1-year high of $46.00. The company has a 50 day moving average price of $30.12 and a 200 day moving average price of $31.64.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Krishnan Viswanadhan sold 2,959 shares of the business’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $27.80, for a total transaction of $82,260.20. Following the completion of the sale, the insider directly owned 5,141 shares in the company, valued at $142,919.80. The trade was a 36.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Sarah Gheuens sold 2,940 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $102,047.40. Following the sale, the insider owned 80,277 shares of the company’s stock, valued at approximately $2,786,414.67. This represents a 3.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 15,582 shares of company stock worth $520,405. 4.93% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Bellevue Group AG lifted its position in shares of Agios Pharmaceuticals by 3.5% during the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock valued at $149,110,000 after buying an additional 124,586 shares in the last quarter. State Street Corp lifted its position in shares of Agios Pharmaceuticals by 37.4% during the 4th quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock valued at $84,604,000 after buying an additional 845,433 shares in the last quarter. Erste Asset Management GmbH lifted its position in shares of Agios Pharmaceuticals by 1.4% during the 4th quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock valued at $76,343,000 after buying an additional 40,000 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Agios Pharmaceuticals by 485.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after buying an additional 2,049,287 shares in the last quarter. Finally, Commodore Capital LP lifted its position in shares of Agios Pharmaceuticals by 0.6% during the 3rd quarter. Commodore Capital LP now owns 2,338,287 shares of the biopharmaceutical company’s stock valued at $93,859,000 after buying an additional 13,287 shares in the last quarter.

Agios Pharmaceuticals News Summary

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Bank of America cut its price target from $44 to $41 but kept a “buy” rating, signaling continued analyst conviction in long‑term upside despite the recent headwinds. Article Title
• Positive Sentiment: HC Wainwright lowered its target from $65 to $50 while maintaining a “buy” rating, indicating bullish analyst views remain albeit with reduced near‑term expectations. Article Title
• Negative Sentiment: Coverage and analysis argue Novo’s late‑stage win materially alters the PK‑activator competitive landscape, a direct challenge to mitapivat’s market opportunity and approval outlook. Article Title
• Negative Sentiment: Market coverage reports that Agios shares plunged after Novo’s PKR activator met its endpoints in a sickle cell study, increasing investor concern about mitapivat’s competitiveness. Article Title
• Negative Sentiment: Newswire reports and analysis summarize Novo’s trial win and emphasize pressure on Agios from a surprise competitor success. Article Title
• Negative Sentiment: Industry coverage explains why Novo’s late‑stage result is a material commercial threat to rivals and why the market punished Agios stock. Article Title
• Negative Sentiment: Consumer/business press pieces highlight the share‑price drop and investor reaction after the surprise Novo data release. Article Title
• Negative Sentiment: Market writeups report a ≈20–25% tumble after the Novo announcement, reflecting rapid repricing of Agios’s sickle‑cell prospects. Article Title

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.